CDDP投与にともなう尿中NAG活性の急性変動についての検討

Abstract

泌尿器科領域の悪性腫瘍8例に対して本剤概ね20 mg/日をTegafur 800 mg/日と共に5日間連用し検討した.1)尿中NAG (N-Acetyl-β, D-Glucosaminidase)活性の表現は1日あたりの総活性で表現すべきである.2) CDDP投与前のNAG活性とCCrから4つのtypeに分け, CDDP投与後のNAG活性の変動から, CDDP継続投与に際し, NAG前値が腎障害を知るうえで重要であり, 投与時期を決定する指標となると考えられた

In the present paper, the acute change of urinary NAG activities following CDDP administration was studied in 8 patients with urological malignant tumors. The activities were measured for 11 days from the day before CDDP administration and were expressed as U/day. According to the NAG activity and creatinine clearance (CCr), the patients were divided into 4 types. In type I (normal NAG activity and normal CCr), the increase of the NAG activity following CDDP administration was transient. In type II (normal NAG activity and low CCr), the NAG activity increased and decreased as in type I, but in type II, the NAG activity rebounded a few days after the completion of CDDP administration. In type III (high NAG activity and normal CCr) and in type IV (high NAG activity and low CCr), the increase of the NAG activities continued longer than in type I, II; especially in type IV, the increase and the prolongation of the NAG activity was prominent. The timing of CDDP administration is considered important to avoid renal toxicity of CDDP.